Trinity Biotech PLC
TRIB1.020USD
-0.260-20.31%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.46MMarket Cap
LossP/E TTM
More Details of Trinity Biotech PLC Company
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Trinity Biotech PLC Info
Ticker SymbolTRIB
Company nameTrinity Biotech PLC
IPO dateOct 21, 1992
CEOGillard (John)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 21
AddressIda Business Park, Bray, Co Wicklow
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code18
Phone01135312955111
Websitehttps://www.trinitybiotech.com/
Ticker SymbolTRIB
IPO dateOct 21, 1992
CEOGillard (John)
Company Executives of Trinity Biotech PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
By RegionUSD
Name
Revenue
Proportion
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
Shareholders
Shareholders
Proportion
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
Shareholder Types
Shareholders
Proportion
Corporation
60.06%
Private Equity
48.04%
Investment Advisor
3.34%
Hedge Fund
1.33%
Research Firm
0.14%
Investment Advisor/Hedge Fund
0.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MiCo IVD Holdings, LLC
447.59K
2.4%
--
--
Dec 17, 2024
Perceptive Advisors LLC
358.00K
1.92%
+358.00K
--
Jun 30, 2025
Hunter Associates Investment Management LLC
87.58K
0.47%
+12.56K
+16.74%
Jun 30, 2025
Renaissance Technologies LLC
11.39K
0.06%
-3.94K
-25.70%
Jun 30, 2025
Two Sigma Investments, LP
3.02K
0.02%
-3.51K
-53.79%
Jun 30, 2025
Moss Adams Wealth Advisors LLC
5.13K
0.03%
--
--
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
4.46K
0.02%
--
--
Jun 30, 2025
Raymond James & Associates, Inc.
5.07K
0.03%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Date
Type
Ratio
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
FAQs
Who are the top five shareholders of Trinity Biotech PLC?
The top five shareholders of Trinity Biotech PLC are:
MiCo IVD Holdings, LLC holds 447.59K shares, accounting for 2.40% of the total shares.
Perceptive Advisors LLC holds 358.00K shares, accounting for 1.92% of the total shares.
Hunter Associates Investment Management LLC holds 87.58K shares, accounting for 0.47% of the total shares.
Renaissance Technologies LLC holds 11.39K shares, accounting for 0.06% of the total shares.
Two Sigma Investments, LP holds 3.02K shares, accounting for 0.02% of the total shares.
MiCo IVD Holdings, LLC holds 447.59K shares, accounting for 2.40% of the total shares.
Perceptive Advisors LLC holds 358.00K shares, accounting for 1.92% of the total shares.
Hunter Associates Investment Management LLC holds 87.58K shares, accounting for 0.47% of the total shares.
Renaissance Technologies LLC holds 11.39K shares, accounting for 0.06% of the total shares.
Two Sigma Investments, LP holds 3.02K shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Trinity Biotech PLC?
The top three shareholder types of Trinity Biotech PLC are:
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC
How many institutions hold shares of Trinity Biotech PLC (TRIB)?
As of 2025Q3, 51 institutions hold shares of Trinity Biotech PLC, with a combined market value of approximately 972.36K, accounting for 12.90% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.08%.
What is the biggest source of revenue for Trinity Biotech PLC?
In FY2023, the Clinical Laboratory business generated the highest revenue for Trinity Biotech PLC, amounting to 42.29M and accounting for 74.41% of total revenue.
